Inactive/Delisted stock
Prime Medicine Stock (NASDAQ:PRME)
Previous Close
$1.36
52W Range
$1.11 - $8.14
50D Avg
$1.45
200D Avg
$2.79
Market Cap
$221.89M
Avg Vol (3M)
$1.94M
Beta
1.55
Div Yield
-
PRME Company Profile
Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. It offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. The company was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.